Candida albicans dimorphism as a therapeutic target

Ilse D Jacobsen1, Duncan Wilson, Betty Wächtler

  • 1Department of Microbial Pathogenicity Mechanisms, Leibniz Institute for Natural Product Research and Infection Biology-Hans Knoell Institute Jena, Beutenbergstraße 11a, D-07745, Jena, Germany.

Summary

Candida albicans dimorphism, switching between yeast and hyphal forms, is crucial for fungal virulence. Understanding this transition could lead to new antifungal drugs targeting this key attribute.